CareDx (CDNA) to Announce Earnings on Tuesday

CareDx (NASDAQ:CDNA) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $102.7560 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

CareDx Stock Performance

NASDAQ CDNA opened at $18.80 on Friday. The stock has a 50-day simple moving average of $19.71 and a 200 day simple moving average of $16.62. CareDx has a twelve month low of $10.96 and a twelve month high of $24.02. The stock has a market capitalization of $966.88 million, a PE ratio of 15.80 and a beta of 2.51.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. BTIG Research boosted their target price on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Craig Hallum downgraded shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a report on Tuesday, January 6th. Weiss Ratings restated a “hold (c-)” rating on shares of CareDx in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $26.67.

Insider Buying and Selling

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer owned 597,405 shares in the company, valued at $12,641,089.80. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 29,636 shares of company stock valued at $625,949 over the last three months. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On CareDx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp increased its stake in CareDx by 6.7% in the fourth quarter. State Street Corp now owns 2,737,752 shares of the company’s stock valued at $51,579,000 after acquiring an additional 171,303 shares during the period. Bamco Inc. NY boosted its holdings in CareDx by 11.2% during the second quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after purchasing an additional 245,651 shares in the last quarter. Deerfield Management Company L.P. acquired a new stake in CareDx during the third quarter valued at approximately $31,857,000. Dimensional Fund Advisors LP grew its stake in shares of CareDx by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,309,980 shares of the company’s stock valued at $24,681,000 after purchasing an additional 93,456 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after buying an additional 170,504 shares in the last quarter.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.